Sweden · Delayed Price · Currency is SEK Apotea AB Earnings Call Transcripts
Fiscal Year 2026
-
Q2 delivered strong revenue growth and profitability, driven by operational efficiency and the launch of apotea.no in Norway. Inventory and CapEx rose with the Varberg center, but the balance sheet remains robust. Growth initiatives and Rx expansion are key priorities.
-
Q1 delivered 10.5% revenue growth and a 5.2% operating margin, with gross margin at a record 28.3% due to successful campaigns and improved procurement. Growth initiatives included a Norway launch and ramp-up at Varberg, while financial targets remain cautious amid global uncertainties.
Fiscal Year 2025
-
Q4 saw 7% revenue growth but weaker profitability due to campaign intensity and Varberg ramp-up costs. Full-year growth was strong at 10.1%, with major investments completed and new growth initiatives underway, including expansion into Norway.
-
Q3 saw 8.9% revenue growth, a 5% EBIT margin, and strong Rx sales, supported by the successful Varberg warehouse launch and efficiency gains. Net cash reached SEK 98 million, with a focus now shifting to external growth and leveraging new capacity.
-
Revenue grew 9.9% to SEK 1.826 billion, driven by strong RX demand and stable gross margins. Profitability improved, with an adjusted EBIT margin of 5.4%, and the Varberg facility is set to boost future efficiency. Net cash position remains strong.
-
Q1 saw 15.2% revenue growth and a rise in EBIT margin to 5.3%, driven by stable demand and improved gross margin. Investments in the Varberg fulfillment center and new AI initiatives are on track, with guidance for EBIT margin maintained at 3-5%.
Fiscal Year 2024
-
Q4 saw 15.8% revenue growth to SEK 1.7 billion, stable margins, and improved profitability, driven by strong Rx sales and automation. Major investments in fulfillment and AI, plus a successful IPO, position the company for further growth and efficiency gains.